Neumora Therapeutics fails to meet Nasdaq minimum bid price requirement
NMRA•Neumora Therapeutics received a Nasdaq notice on October 26, 2026, for failing to meet the $1.00 minimum bid price requirement. It has until April 26, 2027, to regain compliance.
1. Compliance deadline
Neumora Therapeutics has 180 calendar days, until April 26, 2027, to regain compliance. Its common stock must close at a bid price of at least $1.00 for ten consecutive business days.
2. Possible next steps
The company is considering a reverse stock split. A transfer to the Nasdaq Capital Market could provide additional time to comply, subject to meeting other listing requirements; the stock faces delisting if applicable deadlines expire without compliance.
